Rodman & Renshaw initiated coverage of Emergent BioSolutions with a Buy rating and $16 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Secures $30M with Facility Sale
- Medtronic, Palo Alto Networks report quarterly beats: Morning Buzz
- Emergent BioSolutions falls -15.0%
- Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
- Emergent BioSolutions finalizes sale of Baltimore-Camden manufacturing site